172 related articles for article (PubMed ID: 25257727)
1. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Miller KD; Althouse SK; Nabell L; Rugo H; Carey L; Kimmick G; Jones DR; Merino MJ; Steeg PS
Breast Cancer Res Treat; 2014 Nov; 148(1):99-106. PubMed ID: 25257727
[TBL] [Abstract][Full Text] [Related]
2. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer.
Nishimura R; Nagao K; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Higuchi A; Ikeda K
Eur J Cancer; 1997 Aug; 33(9):1407-12. PubMed ID: 9337682
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women.
Ohtsu T; Fujii H; Wakita H; Igarashi T; Itoh K; Imoto S; Kohagura M; Sasaki Y
Cancer Chemother Pharmacol; 1998; 42(1):1-8. PubMed ID: 9619751
[TBL] [Abstract][Full Text] [Related]
5. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
Ganzina F
Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
[TBL] [Abstract][Full Text] [Related]
6. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
Birrell SN; Roder DM; Horsfall DJ; Bentel JM; Tilley WD
J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer.
Koyama H; Tominaga T; Asaishi K; Abe R; Iino Y; Enomoto K; Miura S; Nomura Y; Nakazato H; Abe O
Oncology; 1999; 56(4):283-90. PubMed ID: 10343191
[TBL] [Abstract][Full Text] [Related]
9. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
Palmieri D; Halverson DO; Ouatas T; Horak CE; Salerno M; Johnson J; Figg WD; Hollingshead M; Hursting S; Berrigan D; Steinberg SM; Merino MJ; Steeg PS
J Natl Cancer Inst; 2005 May; 97(9):632-42. PubMed ID: 15870434
[TBL] [Abstract][Full Text] [Related]
10. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
Kloke O; Klaassen U; Oberhoff C; Hartwich G; Szanto J; Wolf E; Heckmann M; Huhn R; Stephan L; Schnepper U; Donsbach GM; Bechtel C; Rudolph R; Berke A; Borquez D; Hawig I; Hirche H; Schindler AE; Seeber S; Becher R
Breast Cancer Res Treat; 1999 May; 55(1):51-9. PubMed ID: 10472779
[TBL] [Abstract][Full Text] [Related]
11. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
[TBL] [Abstract][Full Text] [Related]
14. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
15. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
Etienne MC; Milano G; Namer M
Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
[TBL] [Abstract][Full Text] [Related]
16. Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
Toyama T; Yamashita H; Hara Y; Hikosaka Y; Kobayashi S; Iwase H
Int J Clin Oncol; 2001 Dec; 6(6):306-9. PubMed ID: 11828951
[TBL] [Abstract][Full Text] [Related]
17. Oral high-dose progestins as treatment for advanced breast cancer.
Lundgren S; Kvinnsland S; Utaaker E
Acta Oncol; 1989; 28(6):811-6. PubMed ID: 2532917
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate.
Zaucha R; Sosińska-Mielcarek K; Jassem J
Breast; 2004 Aug; 13(4):321-4. PubMed ID: 15325667
[TBL] [Abstract][Full Text] [Related]
19. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
20. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
Murray A; Clinton O; Earl H; Price M; Moore A
Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
